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Abstract
Due to constitutive expression in cells targeted by human immunodeficiency virus (HIV), and immediate mode of viral
restriction upon HIV entry into the host cell, APOBEC3G (A3G) and APOBEC3F (A3F) have been considered primarily as
agents of innate immunity. Recent bioinformatic and mouse model studies hint at the possibility that mutation of the HIV
genome by these enzymes may also affect adaptive immunity but whether this occurs in HIV-infected individuals has not
been examined. We evaluated whether APOBEC-mediated mutations within common HIV CD8+ T cell epitopes can
potentially enhance or diminish activation of HIV-specific CD8+ T cells from infected individuals. We compared ex vivo
activation of CD8+ T lymphocytes from HIV-infected individuals by wild type HIV peptide epitopes and synthetic variants
bearing simulated A3G/F-induced mutations by measuring interferon-c (IFN-c) production. We found that A3G/F-induced
mutations consistently diminished HIV-specific CD8+ T cell responses against the common epitopes we tested. If this reflects
a significant trend in vivo, then adaptation by HIV to enrich sequences that are favored for mutation by A3G/F (A3G/F
hotspots) in portions of its genome that encode immunogenic CD8+ T cell epitopes would favor CTL escape. Indeed, we
found the most frequently mutated A3G motif (CCC) is enriched up to 6-fold within viral genomic sequences encoding
immunodominant CD8+ T cell epitopes in Gag, Pol and Nef. Within each gene, A3G/F hotspots are more abundant in
sequences encoding epitopes that are commonly recognized due to their HLA restriction. Thus, in our system, mutations of
the HIV genome, mimicking A3G/F activity, appeared to abrogate or severely reduce CTL recognition. We suggest that the
physiological significance of this potential effect in facilitating CTL escape is echoed in the adaptation of the HIV genome to
enrich A3G/F hotspots in sequences encoding CTL epitopes that are more immunogenic at the population level.
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Introduction
APOBEC3G (A3G) and APOBEC3F (A3F) mutate deoxycyti-
dine (dC) to deoxyuridine (dU) in the reverse transcribed nascent
DNA of human immunodeficiency virus (HIV) [1–5]. A3G/F are
constitutively expressed in CD4+ T lymphocytes, macrophages,
and dendritic cells, the targets of HIV [6–12], but are also induced
by interferon (IFN) in these and other cell types [11]. If a host cell
expresses A3G/F, these enzymes infiltrate the virions produced by
said host. In the next infection cycle, they deaminate dC in
signature trinucleotide motifs (CCC and less often TCC for A3G;
TTC for A3F) in the minus strand reverse-transcribed viral DNA,
registering as deoxyguanosine (dG) to deoxyadenosine (dA)
substitutions in the plus strand. These mutations alter reading
frames, terminate translation, and/or produce mutated proteins
[13–17]. In addition to mutating the HIV genome, A3G/F have
also been reported to physically interfere with reverse transcription
and viral genome integration into the host cell [18–20].
In the physiological setting, the effectiveness of A3G/F against
HIV is restricted by several factors. First, the HIV auxiliary
protein viral infectivity factor (Vif) binds to A3G/F and promotes
their degradation [21–24]. Second, entrapment of A3G/F in high
molecular mass (HMM) ribonuclear complexes renders a major
fraction of the cellular pool of enzymes inactive [25–28]. Third,
even in cells where A3G/F introduce a high mutational load into
the invading viral genomes, the final mutational profile in
assembled virions is limited by selection for viral fitness over
successive stages of the viral life cycle, a phenomenon termed
‘‘purifying selection’’ [29]. As a result of these viral counter
measures as well as the filtering process through selection for
fitness, the majority of circulating viruses bear a lesser (sub-lethal)
mutational load in their genome than would reflect the full
enzymatic potential of A3G/F. Regardless of the level of their
anti-viral effectiveness in vivo, APOBECs have classically been
thought of as host restriction innate immune factors largely owing
to their expression pattern and immediate modes of viral
restriction. They presumably play a particularly important role
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in the early phases of HIV infection to limit viral propagation
whilst long-lasting and more specific adaptive immune responses
takes weeks to months to develop fully.
Following the initial innate immune barriers, adaptive immune
responses in the form of anti-viral antibodies and cytotoxic T cells
(CTL) develop and act to contain viral propagation throughout the
course of infection [30]. Robust anti-viral CTL responses are
associated with slower disease progression and lower viremia levels
[31–35]. Mutations in CTL epitopes of HIV favor immune
evasion by reducing CTL recognition and activation [36–40].
Although A3G/F are intrinsic anti-viral barriers that function
early in infection, once the CTL response escalates to effective
levels, the limited action of A3G/F may actually aid HIV by
mutating its CTL epitopes towards immune evasion [19,41]. In
support of this possibility, the most highly mutating sites in HIV
genomes mediating CTL escape are somewhat enriched in A3G
hotspots [41]. However, viral genomes derived from infected
individuals are inherently biased towards immune escape muta-
tions because mutations that enhance CTL recognition would be
rapidly eliminated. Mutations that might conversely improve CTL
recognition, like mutations that would otherwise decrease viral
fitness, would not be reflected in the isolated pool of viral genomes.
On the other hand, a mouse-model study found that A3G-induced
mutations outside HIV peptide epitopes can enhance the HIV-
specific CTL response [42]. This study measured the response of
MHC-matched CTL clones bearing transgenic peptide-specific T
cell receptors (TCR) against peripheral blood mononuclear cells
(PBMCs) infected by HIV produced in A3G-expressing or
deficient cells. Results indicated that A3G-induced mutations
outside CTL epitopes could alter the relative types of peptides
available for CTL recognition. This study indicated for the first
time that A3G can, in principle, modulate the CTL response by
affecting the efficiency of epitope processing and presentation to
CTL. However, the results of this study do not inform as to
whether A3G/F mutations directly within CTL epitopes enhance
or diminish the CTL response or whether the effect is measurable
in the physiological setting of human HIV infection.
In this study, we simulated A3G/F mutations of CTL epitopes
of HIV and measured their effect on recognition by circulating
CD8+ T cells of HLA-matched, HIV-infected individuals ex vivo.
We found that HIV-specific CD8+ T cell recognition was generally
diminished by A3G/F-induced mutations. In silico analysis re-
vealed the greatest enrichment of A3G/F hotspot motifs occurs
within the viral genomic sequences that encode for the most
immunogenic CTL epitopes. Our ex vivo data are consistent with
the potential of A3G/F mutations to promote CTL escape. Our
observation that HIV has evolved strategically-placed A3G/F
mutable hotspots in its genome to maximally direct A3G/F
activity towards CTL escape is further evidence that A3G/F
mutations likely impact adaptive immunity in vivo.
Materials and Methods
In silico Demarcation and Simulation of A3G/F Hotspot
Mutations in CTL Epitopes
The 9229 nucleotide-long genome of HIV isolate BRU was
retrieved from the National Center for Biotechnology Information
(NCBI) website. Isolate BRU was selected due to its representation
of clade B, which is most prevalent in western countries [43].
Portions of the HIV genome encoding known CTL epitopes were
identified using the HIV Molecular Immunology Database
(http://www.hiv.lanl.gov/content/immunology/tables/ctl_summary.
html). A3G/F mutations on the 59 dG located in A3G/F hotspots in
the CTL epitope-coding genomic DNA were simulated in silico to
generate mutated epitopes. For epitopes with multiple hotspots or
those with potential for the generation of novel hotspots as a result of
first-round mutation, multiple mutated versions were considered. Wild
type (wt) and mutant (mut) forms of all selected epitopes were
synthesized to ,90% purity (Peptide 2.0 Inc., VA-US) and used to
measure peptide-specific CTL responses from HLA-matched HIV+
individuals.
Measurement of HIV-specific CD8+ T Cell Recognition
HIV-infected study participants were recruited through the
Newfoundland and Labrador Provincial HIV Clinic in St. John’s,
Newfoundland, and selected on the basis of their HLA class I types
determined for previous immunological studies [44,45]. Informed
written consent was obtained for blood collection and this study
received ethical approval from the Health Research Ethics
Authority of Newfoundland and Labrador for the consent and
experimental protocols (reference #02.157). Cryopreserved
PBMC from appropriate HLA-matched subjects were used as
responder CD8+ T cells. The ELISPOT assay to measure the
frequency of HIV-specific CD8+ T cells has been previously
described [46]. The average of duplicate wells was obtained and
the number of background spots in the negative control well
subtracted. The total number of IFN-c spot forming cells (SFC) in
each well was expressed as IFN-producing SFC/106 PBMC.
Even though the background frequency of IFN-producing
unstimulated PBMC was negligible (typically ,10/106 PBMC),
we only considered .50 SFC/106 PBMC as a positive response.
(In all, 27/77 subjects tested showed a significant response.).
Differences of .25% in SFC between wt and mut were
considered significant.
In silico Analysis of A3G/F Hotspot Frequencies in CTL
Epitopes
The number of hotspots (for A3G: GGG, GGT or GGA; for
A3F: GAA) inside vs. outside CTL epitopes in each HIV gene was
determined by scanning the BRU sequence. To normalize for
gene size, the frequencies of hotspot occurrence were divided by
the total number of nucleotides. These frequencies were calculated
both for all A3G/F hotspots, and also solely for the most
frequently targeted A3G hotspot (GGG). Subsequently, the ratio
(R) of normalized hotspot frequencies inside to outside epitopes
was calculated for each gene. In order to evaluate differences in R
amongst various genes, an index was generated by determining the
average of the R of all genes and dividing the R of each gene by
the average. Thus, an index of .1 indicates an above average
ratio of A3G/F hotspots inside to outside CTL epitopes. We
further conducted the same type of analysis within each gene in
order to compare hotspot frequencies between epitopes restricted
to different HLA alleles (A1, A2, A3, A11, A24, B7, B8, B35, B40,
B44, B53, B57).
Statistical Analysis
The wilcoxon signed-rank test was used to evaluate the
statistical likelihood that introduction of APOBEC-related muta-
tions into HIV CTL epitopes reduces recognition of those
epitopes. Paired values for all Elispot comparisons of wt vs. mut
epitopes were used to calculate statistical significance using
Graphpad Prism 5.0.
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Results
Demarcation of A3G/F Hotspots within Genomic
Sequences Encoding CTL Epitopes and Simulation of
A3G/F-induced Mutations
We identified CTL epitopes in all HIV proteins using the
experimentally-verified HIV molecular immunology database
(http://www.hiv.lanl.gov/content/immunology/tables/ctl_summary.
html). This analysis for Gag is shown in Figure S1A (see Figure S2 for
all genes). We analyzed a number of epitopes restricted to HLA-A2,
B44 and B57. These HLAs were chosen for several reasons: strong
CTL responses to B57-restricted epitopes correlate inversely with
disease progression, and HLA-A2 and B44 are common in the
population and present numerous HIV epitopes [32,47–59]. More-
over, between them, these HLA alleles cover a majority of the
population (http://www.allelefrequencies.net). We examined CTL
epitopes in Gag, Pol and Nef because these contain the HIV peptides
most prominently recognized by CD8+ T cells [60–62]. The genomic
sequences of 123 epitopes from the aforementioned database were
identifiable in the BRU isolate sequence (Gag shown as an example in
Figure S1B; see Figure S3 for all genes). Of these, 98 epitopes (80%)
contained $1 A3G/F hotspot in which A3G/F mutations were
simulated and translated in silico. Epitopes for which the only possible
mutation led to a stop codon or non-conservative changes in HLA
anchor residues (thus impeding presentation by MHC class I) were
excluded. Using these criteria, we selected and synthesized 27 wild
type (wt) epitopes and 64 derivative mutants (mut) thereof (Table 1). Of
the wt epitopes, 7 contained a single A3G or A3F hotspot yielding 1
mut each (example shown in Figure S1c, left panel). The other 20
contained .1 A3G/F hotspot (multiple hotspots separated by .3
nucleotides were considered independently; for example see Figure
S1C, middle panel). These yielded multiple muts, some of which could
occur because the initial A3G/F mutation created a new A3G/F
hotspot that could be mutated again in the same or subsequent
round(s) of viral replication (example shown in Figure S1C, right
panel). Finally, we considered whether genomes containing these mut
epitope-encoding sequences have been reported in a database of
submitted HIV sequences (http://www.hiv.lanl.gov/content/
sequence/QUICK_ALIGN/QuickAlign.html). We found that nearly
all mut epitopes occur in the population. The selected wt and mut
epitopes thus considered (Table 1) were synthesized and evaluated by
ELISPOT for recognition by HIV-specific CD8+ T cells from HLA-
matched subjects.
CD8+ T Cell Recognition of HLA-B57-restricted Epitopes is
Diminished by A3G/F-simulated Mutations
We compared the CD8+ T cell response against 3 HLA-B57-
restricted epitopes in Gag and the corresponding variants with
APOBEC-induced mutations. Of 5 HLA-B57+ subjects (P7, P45,
P71, P166, P197) tested against TSTLQEQIGW and 1 mut, P197
alone had a positive response that was 3-fold higher against the wt
peptide (280 vs. 85 SFC/106 PBMC) (Figure 1a). Three of the
same 5 subjects had positive responses against KAFSPEVIP (P71:
397; P166: 50; P197: 90 SFC/106 PBMC), whilst none had
responses against the mut (Figure 1b). Eight subjects (P7, P20, P45,
P71, P76, P166, P185, P197) were tested for responses against
AISPRTLNAW and 1 mut. Four (P7, P71, P166, P197) had
positive responses. P7 and P166 responded only against the wt
peptide, while P71 and P197 exhibited responses that were 3- and
1.4-fold higher against wt (P71: 895 vs. 273; P197: 160 vs. 112
SFC/106 PBMC) (Figure 1c). Responses against the Nef epitope
GPGVRYPLTFGWCY and 7 muts were compared in 6 subjects
(P20, P45, P68, P76, P166, P185). Only P68 had a response,
and only against the wt peptide (Figure 1d). Taken together, 9
HLA-B57 subjects responded only against the wt epitopes, whilst 3
responded against both the wt and corresponding mut for which
the responses against wt epitopes were 1.4- to 3-fold higher. Thus,
for the HLA-B57-restricted epitopes and subjects we studied,
introduction of signature A3G/F-induced mutations into the
epitopes consistently abrogated or reduced CD8+ T cell recogni-
tion.
A3G/F-simulated Mutations Diminish CD8+ T Cell
Recognition of HLA-A2-restricted Epitopes
We measured recognition of the HLA-A2-restricted Gag
epitope FLGKIWPS and 3 muts by 9 subjects (P3, P18, P30,
P35, P64, P71, P78, P98, P234). Five had positive responses
exclusively against the wt peptide (Figure 2a). Recognition of the
immunodominant Nef epitope FLKEKGGLEGL epitope and 15
muts was assessed in 30 subjects, of whom 4 responded against the
wt peptide. Of these, P211 responded against a single mut with
1.6-fold less magnitude than against the wt peptide (1512 vs. 910
SFC/106 PBMC) (Figure 2b-e). Recognition of 4 HLA-A2-
restricted Pol epitopes and corresponding variants was compared.
The Pol epitope IYQYMDDLYV and 1 mut were tested in 20
subjects, of whom 3 responded with moderately higher responses
against the wt than mut peptides (for wt vs. mut: P35: 147 vs. 92;
P359: 190 vs. 160; P214: 225 vs. 90; P233: 570 vs. 495 SFC/106
PBMC) (Figure 2f). Recognition of ILKEPVHGV and 1 mut was
tested in 17 subjects, of whom 3 responded, comparably against wt
and mut peptides (for wt vs. mut: P35: 2675 vs. 2442; P359: 1380 vs.
1305; P71: 90 vs. 88; P105: 305 vs. 405 SFC/106 PBMC)
(Figure 2g). LVGPTPVNII and 1 mut were tested in 8 subjects,
with 2 responding only against wt (Figure 2h). ALVEICTEM and
1 mut were tested in 11 subjects and only the wt peptide was
recognized in 1 subject (Figure 2i). Altogether, for 6 HLA-A2-
restricted epitopes in Gag, Nef and Pol, 4 were better recognized
by CD8+ T cells as wt peptides, whilst 2 were recognized
comparably well as wt or mut peptides. A3G/F-simulated
mutations in HLA-A2-restricted epitopes thus diminished recog-
nition by CD8+ T cells in the majority of cases.
A3G/F-simulated Mutations Reduce the CD8+ T cell
Response to the Majority of HLA-B44-restricted Epitopes
Recognition of 2 HLA-B44-restricted wt epitopes and corre-
sponding muts in Gag was examined. Sixteen HLA-B44+ subjects
were tested for CD8+ T cell responses against LSEGATPQDL
and 3 muts. Five responded against the wt peptide (P35: 4245;
P57: 712; P67: 775; P133: 1137; P242: 610 SFC/106 PBMC) and
2 had lesser responses against the G to R mut (P35: 3645; P57: 192
SFC/106 PBMC) (Figure 3a). Five subjects were tested for CD8+ T
cell recognition of the Nef epitope KEKGGLEGL and 5 muts, 4
of whom responded to wt only (Figure 3b). Overall, 9 subjects
responded to 2 epitopes restricted to HLA-B44. Of these, 7
responded only to wt, whilst 2 responded to both wt and mut. In
all cases, the response to wt was significantly higher. Therefore, for
the HLA-B44-restricted epitopes and subjects we studied, intro-
duction of signature A3G/F mutations into the epitopes consis-
tently abrogated or reduced CD8+ T cell recognition. In order to
evaluate the statistical significance of our results, we conducted a
Wilcoxon signed-rank test, considering the Elispot results obtained
for all HLA-57, A2- and B44- restricted wt/mut pairs. We
obtained a p-value of 0.0001, which supports statistical signifi-
cance of our finding that the response to mut epitopes was
diminished as a result of APOBEC-simulated mutations.
APOBECs Mediate CTL Escape in HIV+ Individuals
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Table 1. Wild type and A3G/F-mutated epitopes used to evaluate the CD8+ T cell responses of HLA-matched subjects.
Epitope (sequence, origin) Wt/Mut HLA DNA sequence
AISPRTLNAW Gag 146–153 Wt B57 gccatatcacctagaactttaaatgcatgg
AISPKTLNAW Mut B57 gccatatcacctaaaactttaaatgcatgg
KAFSPEVIP Gag 162–170 Wt B57 aaggctttcagcccagaagtgataccc
KAFSPKVIP Mut B57 aaggctttcagcccaaaagtgataccc
TSTLQEQIGW Gag 240–249 Wt B57 actagtacccttcaggaacaaataggatgg
TSTLQKQIGW Mut B57 actagtacccttcaaaaacaaataggatgg
GPGVRYPLTFGWCY Nef 131–144 Wt B57 gggccaggggtcagatatccactgacctttggatggtgctac
GPEVRYPLTFGWCY Mut B57 gggccagaggtcagatatccactgacctttggatggtgctac
GPEVRYPLTFRWCY Mut B57 gggccagaggtcagatatccactgacctttagatggtgctac
GPGVRYPLTFRWCY Mut B57 gggccaggggtcagatatccactgacctttagatggtgctac
GPKVRYPLTFGWCY Mut B57 gggccaaaagtcagatatccactgacctttggatggtgctac
GPKVRYPLTFRWCY Mut B57 gggccaaaagtcagatatccactgacctttagatggtgctac
GPRVRYPLTFGWCY Mut B57 gggccaagggtcagatatccactgacctttggatggtgctac
GPRVRYPLTFRWCY Mut B57 gggccaagggtcagatatccactgacctttagatggtgctac
PIVLPEKDSW Pol 398–407 Wt B57 cctatagtgctgccagaaaaagacagctgg
PIVLPKKDSW Mut B57 cctatagtgctgccaaaaaaagacagctgg
FLGKIWPSHK Gag 433–442 Wt A2 tttttagggaagatctggccttcctacaaggg
FLRKIWPSHK Mut A2 tttttaaggaagatctggccttcctacaaggg
FLEKIWPSHK Mut A2 tttttagaaaagatctggccttcctacaag
FLKKIWPSHK Mut A2 tttttaaaaaagatctggccttcctacaaggg
YVDRFYKTL Gag 296–304 Wt A2 tatgtagaccggttctataaaactcta
YVDQFYKTL Mut A2 tatgtagaccagttctataaaactcta
PLTFGWCYKLV Nef 136–146 Wt A2 ccactgacctttggatggtgctacaagctagta
PLTFRWCYKLV Mut A2 ccactgacctttagatggtgctacaagctagta
VLEWRFDSRL Nef 180–189 Wt A2 gtgttagagtggaggtttgacagccgccta
VLEWKFDSRL Mut A2 gtgttagagtggaagtttgacagccgccta
FLKEKGGLEGL Nef 90–100 Wt A2 tttttaaaagaaaaggggggactggaagggcta
FLKEKRGLEGL Mut A2 tttttaaaagaaaaaaggggactggaagggcta
FLKEKKGLEGL Mut A2 tttttaaaagaaaaaaaaggactggaagggcta
FLKKKGGLEGL Mut A2 tttttaaaaaaaaaggggggactggaagggcta
FLKKKRGLEGL Mut A2 tttttaaaaaaaaaaaggggactggaagggcta
FLKKKKGLEGL Mut A2 tttttaaaaaaaaaaaagggactggaagggcta
FLKKKKRLEGL Mut A2 tttttaaaaaaaaaaaagagactggaagggcta
FLKKKKRLKGL Mut A2 tttttaaaaaaaaaaaaaagactaaaagggcta
FLKKKGGLKGL Mut A2 tttttaaaaaaaaaggggggactaaaagggcta
FLKKKRGLKGL Mut A2 tttttaaaaaaaaaaaggggactaaaagggcta
FLKKKKGLKGL Mut A2 tttttaaaaaaaaaaaagggactaaaagggcta
FLKEKKRLEGL Mut A2 tttttaaaagaaaaaaaaagactggaagggcta
FLKEKKRLKGL Mut A2 tttttaaaagaaaaaaaaagactaaaagggcta
FLKEKGGLKGL Mut A2 tttttaaaagaaaaggggggactaaaagggcta
FLKEKRGLKGL Mut A2 tttttaaaagaaaaaaggggactaaaagggcta
FLKEKKGLKGL Mut A2 tttttaaaagaaaaaaaaggactaaaagggcta
ALVEICTEM Pol 188–196 Wt A2 gcattagtagaaatttgtacagaaatgga
ALVKICTEM Mut A2 gcattagtaaaaatttgtacagaaatgga
LLWKGEGAV Pol 956–964 Wt A2 ctcctctggaaaggtgaaggggcagta
LLWKSEGAV Mut A2 ctcctctggaaaagtaaaggggcagta
LLWKSERAV Mut A2 ctcctctggaaaagtgaaagggcagta
LLWKSEEAV Mut A2 ctcctctggaaaagtgaagaggcagta
ILKEPVHGV Pol 464–472 Wt A2 attctaaaagaaccagtacatggagtgtat
ILKEPVHRV Mut A2 attctaaaagaaccagtacatagagtgtat
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PLOS ONE | www.plosone.org 4 April 2014 | Volume 9 | Issue 4 | e93428
Analysis of A3G/F Hotspot Frequency inside CTL Epitopes
The ex vivo reduction of HIV-specific CD8+ T cell responses by
A3G/F mutations introduced into common HLA-A2, B44 and
B57-restricted epitopes suggests that it would be advantageous for
HIV to adapt towards maximizing A3G/F hotspots in genomic
sequences encoding highly immunogenic or broadly presented
CTL epitopes. To test this, we calculated the ratio (R) of A3G/F
hotspot frequency inside vs. outside CTL epitopes within each
HIV gene, normalizing for sequence length. We considered the
frequencies of all A3G/F hotspots, but because A3G mutates HIV
Table 1. Cont.
Epitope (sequence, origin) Wt/Mut HLA DNA sequence
VIYQYMDDL Pol 334–342 Wt A2 gttatctatcaatacatggatgatttg
VIYQYIDDL Mut A2 gttatctatcaatacatagatgatttg
VLVGPTPVNI Pol 131–140 Wt A2 gtattagtaggacctacacctgtcaacata
VLVRPTPVNI Mut A2 gtattagtaagacctacacctgtcaacata
IYQYMDDLYV Pol 335–344 Wt A2 atctatcaatacatggatgatttgtatgta
IYQYIDDLYV Mut A2 atctatcaatacatagatgatttgtatgta
LLRWGLTTPDKK Pol 364–375 Wt A2 ctgttgaggtggggacttaccacaccagacaaaaaa
LLKWGLTTPDKK Mut A2 ctgttgaagtggggacttaccacaccagacaaaaaa
LVGPTPVNII Pol 132–141 Wt A2 ttagtaggacctacacctgtcaacataatt
LVRPTPVNII Mut A2 ttagtaagacctacacctgtcaacataatt
VLDVGDAYFSV Pol 263–273 Wt A2 gtactggatgtgggtgatgcatatttttcagtt
VLDVSDAYFSV Mut A2 gtactggatgtaagtgatgcatatttttcagtt
LSEGATPQDL Gag 175–184 Wt B44 ttatcagaaggagccaccccacaagattta
LSERATPQDL Mut B44 ttatcagaaagagccaccccacaagattta
LSKRATPQDL Mut B44 ttatcaaaaagagccaccccacaagattta
LSKGATPQDL Mut B44 ttatcaaaaggagccaccccacaagattta
RDYVDRFYKTL Gag 294–304 Wt B44 agagactatgtagaccggttctataaaactcta
RDYVDQFYKTL Mut B44 agagactatgtagaccagttctataaaactcta
KEKGGLEGL Nef 92–100 Wt B44 aaagaaaaggggggactggaagggcta
KEKGGLERL Mut B44 aaagaaaaggggggactggaaaggcta
KEKGGLKRL Mut B44 aaagaaaaggggggactaaaaaggcta
KEKGGLKGL Mut B44 aaagaaaaggggggactgaaagggcta
KEKKRLEGL Mut B44 aaagaaaaaaggggactggaagggcta
KEKRRLEGL Mut B44 aaagaaaagagaagactggaagggcta
PPIPVGEIY Gag 254–262 Wt B35 ccacctatcccagtaggagaaatttat
PPIPVREIY Mut B35 ccacctatcccagtaagagaaatttat
PPIPVRKIY Mut B35 ccacctatcccagtaagaaaaatttat
PPIPVKKIY Mut B35 ccacctatcccagtaaaaaaaatttat
PPIPVGKIY Mut B35 ccacctatcccagtaggaaaaatttat
PPIPVEKIY Mut B35 ccacctatcccagtagaaaaaatttat
TVLDVGDAY Pol 262–270 Wt B35 acagtactggatgtgggtgatgcatat
TVLDVSDAY Mut B35 acagtactggatgtaagtgatgcatat
GPGVRYPLTF Nef 130–139 Wt B35 gggccaggggtcagatatccactgaccttt
GPRVRYPLTF Mut B35 gggccaagggtcagatatccactgaccttt
GPEVRYPLTF Mut B35 gggccagaggtcagatatccactgaccttt
GPKVRYPLTF Mut B35 gggccaaaggtcagatatccactgaccttt
YPLTFGWCY Nef 134–143 Wt B35 tatccactgacctttggatggtgctac
YPLTFRWCY Mut B35 tatccactgacctttagatggtgctac
VPLDEDFRKY Pol 273–382 Wt B35 gttcccttagatgaagacttcaggaagtat
VPLDKDFRKY Mut B35 gttcccttagataaagacttcaggaagtat
VPLDEDFKKY Mut B35 gttcccttagatgaagacttcaaaaagtat
VPLDKDFKKY Mut B35 gttcccttagataaagacttcaaaaagtat
Wild type epitopes and A3G/F-mutated versions thereof used to test the HIV-specific CD8+ T cell response of HLA-matched subjects by ELISPOT are shown. The
polypeptide of origin for each epitope, its restricting HLA allele and the amino acid position of the epitope in HIV-1 Bru are indicated.
doi:10.1371/journal.pone.0093428.t001
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several fold more potently than A3F, and CCC (GGG on the plus
DNA strand) is its preferentially targeted motif [13,27,63,64], we
also considered the frequency of GGG independently (table S1).
Relative enrichment of hotspots inside vs. outside CTL epitopes for
each gene is reflected by an index that constitutes the ratio of the R
value of each gene to the average R of all genes. Considering the
index values for all hotspots, as well as GGG alone, Gag, Pol and
Nef exhibited the highest indices (for GGG: 1.3, 2.1 and 2.0
respectively) (Figure 4a).
We next addressed the suggestion that enrichment of A3G/F
hotspots amongst various epitopes in each gene correlates with
immunogenicity, as defined by the ability to elicit a robust (or
broad, at the population level) CTL response. To examine this, we
categorized epitopes on the basis of their restricting HLA (A1, A2,
A3, A11, A24, B7, B8, B35, B44, B57). For each gene, we tallied
hotspots inside vs. outside epitopes restricted to each HLA allele
(Figure 4b). We observed a strong trend. For genes with the
highest number of experimentally verified CTL epitopes (Gag, Pol,
Env and Nef), the indices for HLA-B57 were.1, with GGG being
over-represented by 1.7- to 4.9-fold. In contrast, the frequency of
GGG motifs in HLA-B35 was .2-fold lower than that of other
HLA-B alleles. The most striking enrichment was observed in Nef,
where all A3G/F hotspots and GGG were respectively 5.7- and
17.6-fold enriched in B44-restricted as compared to B35-restricted
epitopes. Nef contains a single B44-restricted epitope that induces
robust CTL responses in a broad proportion of the population
[32]. We noted that its coding sequence can potentially generate.
20 muts. We also noted a higher frequency of GGG motifs in A3-
restricted epitopes of Gag and Pol (2.1- to 2.3-fold enriched over
epitopes restricted to other HLAs). These results may reflect the
evolution of the viral genome in line with a higher number of CTL
epitopes in these gene segments as well as the prevalence of the A3
allele in the population.
In order to test if there is broad A3G/F hotspot enrichment
within CTL epitopes, we compared the R of A3G/F hotspots
inside to outside CTL epitopes of each gene to the R of hotspots
inside to outside antibody epitopes in Env, which we considered as
a control. The R for antibody epitopes in Env is 0.71 and 0.9 for
all A3G/F hotspots or GGG, respectively. These are 1.3- to 3-fold
lower than the R values for CTL epitopes of Pol (1.06 and 1.63),
Gag (1.16 and 2.60) and Nef (0.89 and 2.45), but interestingly, up
to 7-fold higher than the R values found in the CTL motifs of
other HIV genes (Vif, Vpr, Tat, Rev and Vpu). The average R
value of GGG inside to outside CTL epitopes in all genes is 2-fold
Figure 1. CD8+ T cell response to HLA-B57-restricted wild type and A3G/F-mutated epitopes. Responses of PBMC from HLA-matched
subjects to wild type and mutant epitopes are shown on the Y-axis, as IFN-c SFC (Spot Forming Cells)/106 PBMC. A. Comparison of IFN-c induction
between wild type and a mutant form of the B57-restriced Gag epitope TSTLQEQIGW. B. Comparison of IFN-c induction between wild type and 2
mutant forms of the B57-restriced Gag epitope KAFSPEVIP. C. Comparison of IFN-c induction between wild type and a mutant form of the B57-
restriced Gag epitope AISPRTLNAW. D. Comparison of IFN-c induction between wild type and 7 mutant forms of the B57 restricted Nef epitope
GPGVRYPLTFGWCY.
doi:10.1371/journal.pone.0093428.g001
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Figure 2. CD8+ T Cell response to HLA-A2-restricted wild type and A3G/F-mutated epitopes. Responses of PBMC from HLA-matched
subjects to wild type and mutant epitopes are shown on the Y-axis, as IFN-c SFC/106 PBMC. A. Comparison of IFN-c induction between wild type and
3 mutant forms of the HLA-A2 restricted Gag epitope FLGKIWSPHK. B-E. Comparison of IFN-c induction between wild type and 15 mutant forms of
the HLA-A2 restricted Nef epitope FLKEKGGLEGL. F. Comparison of IFN-c induction between wild type and a mutant form of the HLA-A2 restricted
Pol epitope IYQYMDDLYV. G. Comparison of IFN-c induction between wild type and a mutant form of the HLA-A2 restricted Pol epitope ILKEPVHGV.
H. Comparison of IFN-c induction between wild type and a mutant form of the HLA-A2 restricted Pol epitope LVGPTPVNII. I. Comparison of IFN-c
induction between wild type and a mutant form of the HLA-A2 restricted Pol epitope ALVEICTEM.
doi:10.1371/journal.pone.0093428.g002
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higher than its counterpart for Ab epitopes across all genes
(Figure 4c). Collectively, this analysis suggests 2 levels of
enrichment of A3G/F hotspots of significance for viral escape
from the CTL response: first, enrichment in CTL epitopes of Gag,
Pol and Nef, and second, enrichment in epitopes within each gene
restricted to HLAs that present more immunogenic epitopes (e.g.
HLA-B57) and HLAs that occur more broadly at the population
level (e.g. HLA-B44, A3).
Discussion
The anti-HIV response by CD8+ CTL plays a key role in
controlling viremia as illustrated by the correlation between
disease progression and class I HLA genotype [47,49,65–68]. A
mouse model study found that A3G-induced mutations can
potentially improve the CTL response against HIV-infected cells
in vitro by producing truncated peptides that are more effectively
processed and presented [42]. In contrast, another study proposed
that A3G hotspots in CTL escape sites reduce CTL recognition of
HIV [41]. It is now appreciated that A3G/F may benefit HIV by
contributing to drug resistance and other contextual fitness-
enhancing mutations [19,69,70]. Here we show that A3G/F
mutations consistently compromise adaptive immune responses in
HIV-infected individuals by favoring CTL escape. Nevertheless,
since we did not directly test the effect of random mutations in this
study, we cannot conclude that A3G/F mutations specifically
diminish the CTL response, nor can we extend our observations
beyond the known set of CTL epitopes that have been identified in
HIV, to date. However, we note that multiple previous studies of
the CD8+ T cell response in HIV+ cohorts to epitope variants
adapted at the population level found that .50% of mut epitopes
including hypothetical variants (i.e. like our muts: not sequenced
from the HIV+ individual whose CTL response was tested)
retained their ability to stimulate CD8+ T cells [35,44,45].
Several non-mutually exclusive scenarios can account for our
observations that in our system the simulated A3G/F-induced
reduced CD8+ T cell recognition of HIV. First, it is possible that
some in silico-simulated A3G/F mutations may not have arisen in
the subjects we tested. This is unlikely since we verified that all of
our mut epitopes have been reported at the population level in a
database of HIV CTL epitope variants (http://www.hiv.lanl.gov/
content/sequence/QUICK_ALIGN/QuickAlign.html). Even if
the occurrence of the mutation elicited a response in as low as
,1 in 10,000 CD8+ T cells, it should be detectable by ELISPOT.
It is possible that the decrease in CTL response to mut epitopes
was a product of our particular experimental procedures. Our
finding that several mut epitopes within Pol were equally well
recognized (Figure 2f, g) argues against this. Finally, it is possible
that our observations reflect the physiological effect of A3G/F-
induced mutations within CTL epitopes. In support of this, our
observation that A3G/F hotspots are selectively enriched in CTL
epitope-encoding portions of the HIV genome indicates that the
reduced CTL recognition of A3G/F-mutated epitopes represents
an in vivo phenomenon pronounced enough to leave an evolu-
tionary footprint on the viral genome.
Figure 3. CD8+ T cell response to HLA-B44-restricted wild type and A3G/F-mutated epitopes. Responses of PBMC from HLA-matched
subjects to wild type and mutant epitopes are shown on the Y-axis as IFN-c SFC/106 PBMC. A. Comparison of IFN-c induction between wild type and
3 mutant forms of the HLA-B44 restricted Gag epitope LSEGATPQDL. B. Comparison of IFN-c induction between wild type and 6 mutant forms of the
HLA-B44 restricted Nef epitope KEKGGLEGL.
doi:10.1371/journal.pone.0093428.g003
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The most direct interpretation of our data is that the majority of
A3G/F mutations within CD8+ T cell epitopes reduce peptide
recognition by CD8+ T cells originally activated by the wild type
HIV peptide epitope. Cross-reactive recognition of the mutated
peptide seems unlikely in the case of non-conservative amino acid
substitutions associated with A3G/F mutations such as G to R. If
the mutated peptide were itself immunogenic and present at high
enough levels, then a non-cross-reactive set of CD8+ T cells would
be expected to arise against the new epitope. The reduced but
apparent reactivity with some mutated epitopes could thus stem
Figure 4. Relative frequency of A3G/F hotspot motifs inside vs. outside CTL epitopes in HIV genes. A. For each HIV gene, the frequency
of A3G/F hotspots (either all hotspots: GGG, GGA, GGT, GAA, or GGG alone) was calculated in genomic sequences that encode CTL epitopes and
sequences that do not encode for CTL epitopes. Normalized frequencies were calculated by taking into account the total nucleotide length of the
sequence. For each HIV gene, the normalized frequency of A3G/F hotspots inside sequences that encode CTL motifs was divided by the normalized
frequency of A3G/F hotspots in sequences that do not encode CTL epitopes to generate a Ratio (R-value). The average of R-values amongst all HIV
genes was determined and each R-value was divided by the average to obtain the index value, which reflects enrichment of hotspots within CTL
epitopes, relative to other HIV genes. B. The same analysis as panel A was conducted within each HIV gene to compare the relative enrichment of
A3G/F hotspots in sequences that encode CTL epitopes restricted to different HLA alleles. C. Comparison of A3G/F enrichment in CTL epitopes vs. the
portions of the Env gene that encode antibody recognition epitopes. Average R-value for the CTL epitopes of all genes (average of all R values from
panel A) was compared to the R value of A3G/F hotspots inside/outside sequences encoding antibody recognition motifs within Env. Index value of 1
is shown as a scale because an index .1 indicates relative enrichment.
doi:10.1371/journal.pone.0093428.g004
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either from partial cross-reactivity of CD8+ T cells activated by the
wild type epitope or from a smaller, non-overlapping CD8+ T cell
response selectively activated by the new, A3G/F-mutated
epitope. Studies of the T cell response at the clonal level and of
endogenous viral sequences found in each HIV+ individual would
be required to further address the issue of cross-reactivity vs.
activation of a non-overlapping set of T cells against a de novo
A3G/F-derived epitope. Based on previous studies, cross-reactivity
is quite likely in the case of conservative or semi-conservative
mutations introduced into epitopes by A3G/F [35]. Rare
conservative A3G/F-induced mutations, such as the M to I
mutation in the HLA A2-restricted epitope IYQYMDDLYV,
were more likely to elicit comparable responses. It is probable that
A3G/F-mutated epitopes are less efficient at activating CTL
‘‘selected’’ to recognize the wt epitope due to non-conservative
mutations and the effect thereof on recognition by the T cell
receptor. In the setting within which we tested the impact of A3G/
F mutations on activation of CD8+ T cells from HIV-infected
individuals, reduction or abrogation of CD8+ T cell activation was
the rule.
The significance of our results lies in demonstration of viral
access to multiple avenues of mutational escape from immune
recognition. Infidelity and lack of proof-reading for reverse
transcription results in 1 to 2 mutations/viral genome/round of
replication [71–75]. While this level of mutation ensures that
escape mutations occur at the level of the overall virus population,
it would still leave the majority of viruses susceptible until selective
expansion of the mutated virus allowed it to become predominant.
The need to achieve expeditious escape from a diverse T cell
response raises a higher mutational barrier. In this context, A3G is
a highly processive enzyme that by conservative estimates, can
introduce tens of mutations in a viral genome in a single
replication round, and hundreds of mutations in a viral genome
in a replication round when its activity is unhindered by Vif
[13,76]. Indeed, turning off (and likely also turning down) the
expression and/or A3G-restricting effectiveness of Vif has been
shown to be a means by which HIV fine-tunes the increase in A3G
activity in order to overcome other selective pressures such as anti-
viral drugs [77,78]. Taken together with selective positioning of
A3G motifs within CD8+ T cell epitopes over most other portions
of the HIV genome, this provides HIV with a substantially more
robust mechanism of generating mutations that affect immune
recognition. Furthermore, the specificity of A3G/F, which often
led to non-conservative amino acid changes in CTL epitopes that
we examined, positively skews the likelihood of mutation
contributing to immune escape.
Our findings contrast with those of a recent mouse model study
showing that A3G mutations promote the CTL response through
introducing stop codons leading to the generation of truncated
proteins [42]. This study demonstrated the potential of A3G/F to
increase HIV immunogenicity through an indirect mechanism
involving mutation of sequences outside of actual CTL epitopes,
which modulates the efficacy of epitope production and/or
presentation. Here we report that the direct action of A3G/F
within sequences encoding CD8+ T cell epitopes most often has
the opposite effect in HIV-infected individuals. Whilst the mouse
study utilized transgenic T cell receptor-bearing T cells in a well
defined animal model and elegantly showed that APOBEC action
can impact the CTL response, the work presented here takes into
account a diverse set of human subjects with respect to differences
in HLA makeup, anti-viral drug treatment and stage of HIV
infection. In this context, we note that our data reflect a general
physiological effect of A3G/F-induced mutations within CTL
epitopes for the cohort of HIV-infected subjects we studied. What
exceptions there may be at the individual level remains to be
tested. Our observation that A3G/F hotspots are enriched in CTL
epitope-encoding sequences of the HIV genome argues that the
magnitude of CTL escape as a result of A3G/F-induced mutations
is significant enough to have left its evolutionary footprint on the
viral genome. Further work is required to shed light on the
molecular and cellular pathways through which these DNA-
mutating enzymes alter CTL recognition of infected cells, as well
as to better understand the role of A3G/F-induced mutations
outside CTL epitopes in affecting the processing and presentation
of HIV peptides to T cells.
Supporting Information
Figure S1 Delineation of the amino acid and DNA sequences of
CTL epitopes. A. locations of CTL epitopes in Gag, in the HIV-1
Bru isolate sequence of HIV. The brackets indicate epitopes on the
peptide sequence. Epitopes are shown in different colors
depending on HLA allele restriction, which is indicated above
the bracket. Dashed lines display epitopes that are devoid of A3G/
F hotspots and continuous lines show epitopes that harbor A3G/F
hotspots. B. locations of the viral genomic sequences that encode
CTL epitopes in Gag in the HIV-1 Bru isolate plus-sense strand.
Colors delineate the sequences encoding CTL epitopes from the
surrounding DNA, but do not otherwise correspond to any
common features amongst genes or epitopes. C. Simulation of
A3G/F-mediated mutations of CTL epitopes. Wild-type epitopes
and their encoding DNA sequence are shown. A3G/F targeting
hotspots in the plus-sense epitope encoding sequence are
underlined and colored in blue. Simulated A3G/F-mediated G
to A mutations in the viral genomic sequence and the resulting
amino acid mutations in CTL epitopes are shown below in red.
Left panel shows a typical epitope with a single possible mutation.
Middle panel shows a typical epitope with Multiple independent
mutations. Hotspots separated by .3 nucleotides were considered
as independent and mutant epitopes bearing either mutation or
combinations of multiple mutations were considered. Right panel
shows a typical epitope with multiple sequential mutations. For
hotspots where an initial A3G/F-mediated mutation can generate
a new A3G/F hotspot which may be mutated in the same or a
subsequent replication cycle, variants bearing different combina-
tions of mutations were considered.
(PDF)
Figure S2 Map of all HIV-1 Bru isolate CTL epitopes across the
viral proteome. HIV proteins are shown individually (A: Pol, B:
Rev, C: Vif, D: Nef, E: Vpr, F: Env, G: Gag, H: Tat). The
brackets indicate epitopes on the peptide sequence. Epitopes
restricted to different HLA alleles are shown in different colors and
the restricting HLA is indicated above the bracket. Broken lines
display epitopes with no A3G/F hotspots and continuous lines
show epitopes that harbor A3G/F hotspots.
(PDF)
Figure S3 Map of the viral genomic sequences that encode CTL
epitopes in the HIV-1 Bru isolate plus-sense coding DNA.
Sequence of each gene is shown (A: Pol, B: Rev, C: Vif, D:
Nef, E: Vpr, F: Env, G: Gag, H: Tat). Colors differentiate
sequences encoding CTL epitopes from the surrounding DNA.
Colors do not otherwise correspond to any common features
amongst genes or epitopes.
(PDF)
Table S1 Relative enrichment of A3G/F hotspot inside/outside
CTL epitopes in HIV genes. For each HIV gene, the frequency of
A3G/F hotspots (either all hotspots: GGG, GGA, GGT, GAA, or
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GGG alone) was calculated in genomic sequences that encode for
CTL epitopes and those that do not encode for CTL epitopes.
Normalized frequencies were calculated by taking into account the
total nucleotide length of the sequence. For each HIV gene, the
normalized frequency of A3G/F hotspots inside sequences that
encode CTL motifs was divided by the normalized frequency of
A3G/F hotspots in sequences that do not encode CTL epitopes to
generate a Ratio (R-value). The average of R-values was
determined and each R-value was divided by the average to
obtain the index value and allow for determination of the relative
enrichment of hotspots within the CTL epitopes of each gene, as
compared to the average ratio of hotspots inside to outside CTL
epitopes. An index value .1 indicates relative enrichment.
(PDF)
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